Citations

Clear

89 citation(s) found for "Rowland, C".

Examination Under Anesthesia for Evaluation of Anterior Shoulder Instability
Oliashirazi, Ali, Mansat, Pierre , Cofield, Robert H. , Rowland, Charles M.

Mayo Clinic

The American Journal of Sports Medicine | July 19, 2017 | Volume: 27 | Issue: 4 | Pages: 464-468

10.1177/03635465990270041001 | PMID 10424216 Get It

Thirty patients with unilateral, traumatic recurrent anterior instability were assessed by examination under anesthesia of both shoulders in the anterior, anteroinferior, inferior, posterior, and posteroinferior directions while the examiner controlled the patients' arm rotation. There were significant side-to-side differences in humeral head translation, depending on arm rotation. Humeral head translation was significantly greater in the abnormal shoulder only in the anteroinferior direction with 40° and 80° of external rotation of the arm. Defining an “abnormal” examination as grade 3 translation (translation of the humeral head up onto the glenoid rim) or grade 4 translation (translation of the humeral head over the glenoid rim, that is, dislocated) and translation two grades greater than the contralateral uninjured side, the test sensitivity was 83%, and the test specificity was 100%. Assessing humeral head translation by examination under anesthesia is a useful adjunct to the diagnostic tools for shoulder instability, but the number of tests should be expanded to include the anteroinferior and posteroinferior directions, and the tests should be done with the arm in varying degrees of rotation.
Long‐term follow‐up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B–cell non‐Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) M
Witzig, Thomas E. , Johnston, Patrick B. , LaPlant, Betsy, Kurtin, Paul J. , Pederson, Levi , Moore, Dennis F., Nabbout, Nassim H., Nikcevich, Daniel A., Rowland, Kendrith M. , LaPlant, Betsy R, Pederson, Levi D , Witzig, T.E. , Grothey, Axel

Mayo Clinic

American Journal of Hematology | June 14, 2017 | Volume: 92 | Issue: 10 | Pages: 1004-1010

10.1002/ajh.24824 | PMID 28614905 Get It

AbstractPatients with relapsed aggressive non‐Hodgkin lymphoma (NHL) are often treated with platinum‐based chemoimmunotherapy regimens in preparation for autologous stem cell transplant. We sought to reduce toxicity and maintain efficacy by using oxaliplatin with rituximab, cytarabine and dexamethasone (ROAD) in a phase II clinical trial in patients who had relapsed after one prior regimen. ROAD was delivered q21 days and consisted of rituximab 375 mg/m2 IV weekly x 4 doses (cycle 1 only); dexamethasone 40 mg PO/IV d2 – 5; oxaliplatin 130 mg/m2 IV day 2; cytarabine 2000 mg/m2 IV × two doses on days 2 to 3; and pegfilgrastim 6 mg SC on day 4. Forty‐five eligible patients were accrued between 2006 and 2008. Patient characteristics were a median age of 69 years; 96% had received prior rituximab; 53% were within one year of diagnosis. The median number of cycles received was 2 (range, 1‐6). Forty‐four % received ROAD as an outpatient. The overall response rate was 71% with 27% (12/45) CR and 44% (20/45) PR. Forty‐four % (20/45) of all patients and 69% (18/26) of patients whom responded after 2 cycles proceeded to transplant. Median overall survival was 26 mos (95% CI: 7.3 mos—not reached) and median progression‐free survival was 11 mos (95% CI: 6—104 mos). There was no grade 3/4 nephrotoxicity; the rate of grade 3/4 neuropathy was 4%. Forty‐two percent of all patients and 69% of patients transplanted remain alive at 5 years. ROAD represents an acceptable salvage therapeutic option for patients with relapsed aggressive NHL.
Pemetrexed (Pem)/gemcitabine (Gem) as front-line therapy for advanced NSCLC: A randomized, phase II trial of three schedules
Adjei, Alex A. , Nair, S., Reuter, Nicholas F., Mandrekar, Sumithra J. , Kuross, Steven A., Rowland, K. M., Steen, Preston D. , Hillman, Shauna L., Jett, James R., Nair, S., Schild, Steven E.

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 7070-7070

10.1200/jco.2004.22.90140.7070 Get It

NCCTG trial of gemcitabine for relapsed B-cell chronic lymphocytic leukemia
Call, Tim G., Constantinou, Constantina , Kahanic, Stephen P., Rowland, K. M., Dakil, S. R., Hoering, Antje , Li, C. Y., Dewald, G, Call, Timothy G., Dakil, S. R., Kay, Neil E. , Witzig, Thomas E.

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 6726-6726

10.1200/jco.2004.22.90140.6726 Get It

A phase II study of a combination of pemetrexed (Pem) and gemcitabine (Gem) in patients with metastatic breast cancer (MBC): An NCCTG study
X., C., Steen, Preston D. , Rowland, K. M., Niedringhaus, Robert D., Kugler, J. W., Perez, Edith A. , Adjei, Alex A. , Ma, C. X., Ingle, James N.

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 639-639

10.1200/jco.2004.22.90140.639 Get It

Phase III Clinical Trial of the Combination of Cisplatin, Dacarbazine, and Carmustine With or Without Tamoxifen in Patients With Advanced Malignant Melanoma
Creagan, Edward T. , Dalton, Robert J., Pitot, Henry C., Long, Harry J., Veeder, Michael H., Vukov, Allen M., Rowland, Kendrith M. , Krook, James E., Michalak, John C., Suman, Vera J.

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 17 | Issue: 6 | Pages: 1884-1884

10.1200/jco.1999.17.6.1884 | PMID 10561229 Get It

PURPOSE: A prospective randomized phase III clinical trial was conducted to assess whether the addition of tamoxifen (TAM) to the three-agent regimen of cisplatin (CDDP), dacarbazine (DTIC), and carmustine (BCNU) significantly increased the progression-free survival and overall survival of patients with advanced malignant melanoma. PATIENTS AND METHODS: Patients with advanced malignant melanoma were treated with CDDP + DTIC + BCNU (CDB) with or without TAM. The dose schedule was CDDP 25 mg/m2 given intravenously (IV) for 30 to 45 minutes in 500 mL of dextrose and ½ normal saline (NS) on days 1 to 3 of a 3-week cycle; DTIC 220 mg/m2 IV for 1 hour in 500 mL of dextrose and ½ NaCl on days 1 to 3 of a 3-week cycle; BCNU 150 mg/m2 IV for 2 to 3 hours in 750 to1,000 mL of dextrose and 5% water onday 1 of every odd 3-week cycle; and TAM 20 mg taken orally every morning. RESULTS: There were 184 eligible patients enrolled. These patients were observed until death or for a minimum of 1.3 years. At last contact, 12 were still alive. The median time to progression was 3.4 months on the CDB arm and 3.1 months on the CDB + TAM arm. The median survival time was 6.8 months with CDB and 6.9 months with CDB + TAM. Progression-free survival (P = .429) and overall survival (P = .545) were not found to differ by treatment. CONCLUSION: The addition of TAM to this three-agent regimen of CDB was not found to provide a meaningful clinical advantage in the treatment of patients with advanced malignant melanoma.
Randomized Comparison of Megestrol Acetate Versus Dexamethasone Versus Fluoxymesterone for the Treatment of Cancer Anorexia/Cachexia
Loprinzi, Charles L. , Kugler, John W., Sloan, Jeff A. , Mailliard, James A., Krook, James E., Wilwerding, Mary B., Rowland, Kendrith M. , Camoriano, John , Novotny, Paul J. , Christensen, Bradley J.

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 17 | Issue: 10 | Pages: 3299-3306

10.1200/jco.1999.17.10.3299 | PMID 10506633 Get It

PURPOSE: Previous double-blind, placebo-controlled, randomized clinical trials have demonstrated that both corticosteroids and progestational agents do partially alleviate cancer anorexia/cachexia. Pilot information suggested that an anabolic corticosteroid might also improve appetites in patients with cancer anorexia/cachexia. The current trial was developed to compare and contrast a progestational agent, a corticosteroid, and an anabolic corticosteroid for the treatment of cancer anorexia/cachexia. PATIENTS AND METHODS: Patients suffering from cancer anorexia/cachexia were randomized to receive either dexamethasone 0.75 mg qid, megestrol acetate 800 mg orally every day, or fluoxymesterone 10 mg orally bid. Patients were observed at monthly intervals to evaluate weight changes and drug toxicity. Patients also completed questionnaires at baseline and at monthly intervals to evaluate appetites and drug toxicities. RESULTS: Fluoxymesterone resulted in significantly less appetite enhancement and did not have a favorable toxicity profile. Megestrol acetate and dexamethasone caused a similar degree of appetite enhancement and similar changes in nonfluid weight status, with nonsignificant trends favoring megestrol acetate for both of these parameters. Dexamethasone was observed to have more corticosteroid-type toxicity and a higher rate of drug discontinuation because of toxicity and/or patient refusal than megestrol acetate (36% v 25%; P = .03). Megestrol acetate had a higher rate of deep venous thrombosis than dexamethasone (5% v 1%; P = .06). CONCLUSION: Whereas fluoxymesterone clearly seems to be an inferior choice for treating cancer anorexia/cachexia, megestrol acetate and dexamethasone have similar appetite stimulating efficacy but differing toxicity profiles.
Phase III double-blinded, randomized trial to evaluate the use of black cohosh in the treatment of hot flashes: A North Central Cancer Treatment Group study
Pockaj, Barbara A. , Loprinzi, Charles L. , Stella, Philip J., Barton, Debra L. , Sloan, Jeff A. , Rao, Ravi , Fitch, Tom R., Rowland, Kendrith M. , Novotny, Paul J. , Gallagher, J.

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 8013-8013

10.1200/jco.2005.23.16_suppl.8013 Get It

Phase II trial of oral vinorelbine for treatment of metastatic breast cancer in women 65 years and older: N003A
Baweja, Mansoina, Fitch, Tom R., Mailliard, J A, Bernath, Albert M., Rowland, Kendrith M. , Kaur, Judith S. , Perez, Edith A. , Suman, Vera J. , Alberts, Steven R.

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 740-740

10.1200/jco.2005.23.16_suppl.740 Get It

Results of 3rd line therapy on N9841: a randomized phase III trial of oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) versus irinotecan (CPT-11) in patients (pts) with advanced colorectal cancer (CRC) previously treated with prior 5FU chem
Rowland, Kendrith M. , Pitot, Henry C., Philip, P. A., Mitchell, Edith P. , Mailliard, J A, Goldberg, Richard M. , Sargent, Daniel J. , Alberts, Steven R.

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 3519-3519

10.1200/jco.2005.23.16_suppl.3519 Get It